Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017

Date: December 13, 2017
Pages: 1575
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G49699B5CD9EN
Leaflet:

Download PDF Leaflet

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 106, 65, 1, 8, 155, 23 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 12, 14, 1, 36 and 11 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Glioblastoma Multiforme (GBM) - Overview
Glioblastoma Multiforme (GBM) - Therapeutics Development
Glioblastoma Multiforme (GBM) - Therapeutics Assessment
Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
Glioblastoma Multiforme (GBM) - Drug Profiles
Glioblastoma Multiforme (GBM) - Dormant Projects 1503
Glioblastoma Multiforme (GBM) - Discontinued Products 1515
Glioblastoma Multiforme (GBM) - Product Development Milestones 1517
Appendix 1531

LIST OF FIGURES

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2017 54
Number of Products under Development by Companies, H2 2017 55
Number of Products under Development by Universities/Institutes, H2 2017 71
Number of Products by Top 10 Targets, H2 2017 102
Number of Products by Stage and Top 10 Targets, H2 2017 102
Number of Products by Top 10 Mechanism of Actions, H2 2017 113
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 113
Number of Products by Top 10 Routes of Administration, H2 2017 124
Number of Products by Stage and Top 10 Routes of Administration, H2 2017 124
Number of Products by Top 10 Molecule Types, H2 2017 126
Number of Products by Stage and Top 10 Molecule Types, H2 2017 126

COMPANIES MENTIONED

AbbVie Inc
Accurexa Inc
Actuate Therapeutics Inc
Aduro BioTech Inc
Advantagene Inc
Advenchen Laboratories LLC
Affimed GmbH
Agenus Inc
Ambrx Inc
Amgen Inc
Ampio Pharmaceuticals Inc
AngioChem Inc
Apac Biotech Pvt Ltd
apceth Biopharma GmbH
APIM Therapeutics AS
Apogenix AG
Ariad Pharmaceuticals Inc
Arog Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Athenex Inc
Basilea Pharmaceutica Ltd
Batu Biologics Inc
Bayer AG
Beactica AB
BeiGene Ltd
Berg LLC
Bexion Pharmaceuticals LLC
BeyondSpring Pharmaceuticals Inc
Bio-Path Holdings Inc
Bioasis Technologies Inc
BioCancell Ltd
Biovista Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Cantex Pharmaceuticals Inc
Cavion LLC
Celgene Corp
Celldex Therapeutics Inc
Cellmid Ltd
Celsion Corp
ChemoCentryx Inc
Coherus BioSciences Inc
Cortice Biosciences Inc
Critical Outcome Technologies Inc
Curtana Pharmaceuticals Inc
Cynata Therapeutics Ltd
CytoVac AS
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals LLC
DEKK-TEC Inc
DelMar Pharmaceuticals Inc
Diffusion Pharmaceuticals Inc
Dr. Reddy's Laboratories Ltd
Ecrins Therapeutics SAS
Eisai Co Ltd
Eli Lilly and Co
EnGeneIC Ltd
Enterome Bioscience SA
EntreChem SL
ERC Belgium SA
Erytech Pharma SA
Evotec AG
F-star Biotechnology Ltd
F. Hoffmann-La Roche Ltd
FirstString Research Inc
Fujifilm Holdings Corporation
Gene Techno Science Co Ltd
Genentech Inc
Genisphere LLC
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
GlioPharma ApS
GtreeBNT Co Ltd
GW Pharmaceuticals Plc
Hamlet Pharma AB
Hanmi Pharmaceuticals Co Ltd
Humanigen Inc
Hutchison MediPharma Ltd
Immatics Biotechnologies GmbH
Immune Pharmaceuticals Inc
ImmunoCellular Therapeutics Ltd
Immunomedics Inc
Immunomet Therapeutics Inc
Immunomic Therapeutics Inc
Incyte Corp
Infinity Pharmaceuticals Inc
Innovation Pharmaceuticals Inc
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
Insys Therapeutics Inc
Iovance Biotherapeutics Inc
Ipsen SA
Janpix Inc
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
Kadmon Corp LLC
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Kite Pharma Inc
Komipharm International Co Ltd
Kringle Pharma Inc
Kyorin Pharmaceutical Co Ltd
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings Inc
Loxo Oncology Inc
Mabion SA
MacroGenics Inc
Medesis Pharma SA
Medicenna Therapeutics Corp
MedImmune LLC
Merck & Co Inc
Merck KGaA
Midatech Pharma Plc
Millennium Pharmaceuticals Inc
MimiVax LLC
Molecular Templates Inc
Moleculin Biotech Inc
Mycenax Biotech Inc
NanoCarrier Co Ltd
Nanomerics Ltd
Nektar Therapeutics
Neonc Technologies Inc
NewLink Genetics Corp
Northwest Biotherapeutics Inc
Novartis AG
Noxopharm Ltd
Noxxon Pharma AG
Nuo Therapeutics Inc
NuvOx Pharma LLC
Omniox Inc
Oncobiologics Inc
Oncodesign SA
Onconova Therapeutics Inc
OncoResponse Inc
Oncternal Therapeutics Inc
Ono Pharmaceutical Co Ltd
Orphit SAS
Oryx GmbH & Co KG
Ovensa Inc
Peloton Therapeutics Inc
Peptomyc SL
Peregrine Pharmaceuticals Inc
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
PharmaCyte Biotech Inc
Pharmicell Co Ltd
Phoenix Biotechnology Inc
PIQUR Therapeutics AG
Plex Pharmaceuticals Inc
Plexxikon Inc
Prana Biotechnology Ltd
PTC Therapeutics Inc
Puma Biotechnology Inc
Regulus Therapeutics Inc
ReNeuron Group Plc
Rgenix Inc
Richter Gedeon Nyrt
Sanofi
Sapience Therapeutics Inc
Scancell Holdings Plc
Sellas Life Sciences Group Ltd
Sigma-Tau SpA
SignPath Pharma Inc
Silenseed Ltd
SOM Biotech SL
Sorrento Therapeutics Inc
StemGen SpA
Stemline Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Sunesis Pharmaceuticals Inc
Susavion Biosciences Inc
Symphogen A/S
Synactix Pharmaceuticals Inc
Systimmune Inc
Terpenoid Therapeutics Inc
Theralase Technologies Inc
Therapeia GmbH & Co KG
Tocagen Inc
TRACON Pharmaceuticals Inc
Transgene SA
Trillium Therapeutics Inc
TVAX Biomedical Inc
Tyme Technologies Inc
Upsher-Smith Laboratories Inc
Vascular Biogenics Ltd
Vault Pharma Inc
Vaximm AG
VBI Vaccines Inc
VCN Biosciences SL
ViraTherapeutics GmbH
Vyriad Inc
X4 Pharmaceuticals Inc
Xintela AB
Yooyoung Pharm Co Ltd
ZIOPHARM Oncology Inc

Global Markets Direct's, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014', provides an overview of the GBM therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for GBM, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for GBM and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

The material was prepared in November, 2014.

LIST OF TABLES

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.13), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.14), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Products under Development by Companies, H2 2017 (Contd.13), H2 2017
Products under Development by Companies, H2 2017 (Contd.14), H2 2017
Products under Development by Companies, H2 2017 (Contd.15), H2 2017
Products under Development by Companies, H2 2017 (Contd.16), H2 2017
Products under Development by Companies, H2 2017 (Contd.17), H2 2017
Products under Development by Companies, H2 2017 (Contd.18), H2 2017
Products under Development by Companies, H2 2017 (Contd.19), H2 2017
Products under Development by Companies, H2 2017 (Contd.20), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.8), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.9), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.8), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.9), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Number of Products by Stage and Molecule Type, H2 2017 (Contd.1), H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Accurexa Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Actuate Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Advantagene Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ambrx Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Apac Biotech Pvt Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by apceth Biopharma GmbH, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by APIM Therapeutics AS, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Apogenix AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ariad Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Arog Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca Plc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Athenex Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Batu Biologics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bayer AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Beactica AB, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by BeiGene Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Berg LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bio-Path Holdings Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bioasis Technologies Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Co, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corp, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cellmid Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corp, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Critical Outcome Technologies Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Curtana Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cynata Therapeutics Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by CytoVac AS, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by DelMar Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Co, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Enterome Bioscience SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by EntreChem SL, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Erytech Pharma SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by F-star Biotechnology Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Fujifilm Holdings Corporation, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Gene Techno Science Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Genentech Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Genisphere LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by GlioPharma ApS, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by GtreeBNT Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Hamlet Pharma AB, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Humanigen Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Hutchison MediPharma Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immatics Biotechnologies GmbH, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immune Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immunomedics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immunomet Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Incyte Corp, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Infinity Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Inspyr Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Insys Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Iovance Biotherapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ipsen SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Janpix Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Juno Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corp LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Kazia Therapeutics Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Kite Pharma Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Komipharm International Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Kringle Pharma Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Loxo Oncology Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Mabion SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by MacroGenics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Medesis Pharma SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics Corp, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by MedImmune LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Merck KGaA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Midatech Pharma Plc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by MimiVax LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Molecular Templates Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Moleculin Biotech Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by NanoCarrier Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Nanomerics Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Nektar Therapeutics, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Neonc Technologies Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by NewLink Genetics Corp, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Noxopharm Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Nuo Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by NuvOx Pharma LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Omniox Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Oncobiologics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by OncoResponse Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Oncternal Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Orphit SAS, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co KG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ovensa Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Peloton Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Peptomyc SL, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Pharma Mar SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by PharmaCyte Biotech Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Pharmicell Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Phoenix Biotechnology Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by PIQUR Therapeutics AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Plex Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by PTC Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Puma Biotechnology Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by ReNeuron Group Plc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Rgenix Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Richter Gedeon Nyrt, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sanofi, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sapience Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Scancell Holdings Plc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sellas Life Sciences Group Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau SpA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by SignPath Pharma Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Silenseed Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by SOM Biotech SL, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sorrento Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by StemGen SpA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sunesis Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Susavion Biosciences Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Symphogen A/S, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Synactix Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Systimmune Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Theralase Technologies Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Therapeia GmbH & Co KG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Transgene SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Trillium Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Tyme Technologies Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Vault Pharma Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by VBI Vaccines Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by VCN Biosciences SL, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by ViraTherapeutics GmbH, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Vyriad Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by X4 Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Xintela AB, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Yooyoung Pharm Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology Inc, H2 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 1546
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd.1), H2 2017 1547
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd.2), H2 2017 1548
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd.3), H2 2017 1549
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd.4), H2 2017 1550
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd.5), H2 2017 1551
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd.6), H2 2017 1552
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd.7), H2 2017 1553
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd.8), H2 2017 1554
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd.9), H2 2017 1555
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd.10), H2 2017 1556
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd.11), H2 2017 1557
Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2017 1558
Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2017 (Contd.1), H2 2017 1559

Skip to top


Ask Your Question

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: